The U.S. Food and Drug Administration said on Friday it approved class="mandelbrot_refrag"> Biogen Idec Inc's long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders. Hemophilia A is a rare, inherited blood-clotting disorder that can lead to prolonged bleeding, bruising and joint and tissue damage. It is caused by deficient levels in the body of factor VIII, a protein needed to clot the blood. The FDA's ruling followed its approval in March of Biogen's hemophilia B treatment, Alprolix. Biogen developed both drugs with Swedish Orphan Biovitrum AB, or Sobi, and expects the products to form the basis of a new non-malignant blood disorder portfolio. "We see Alprolix and Eloctate as the anchor tenants in a growing franchise," said Douglas Williams, Biogen's head of research and development. "We're in this space to stay." Biogen's bigge